Scholarlink

Objective <p>The APS ACTION Registry was created to study long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients. The objectives of this study were to examine the ethnoracial differences in clinical and laboratory characteristics of aPL-positive patients with no other systemic autoimmune rheumatic diseases (SARDs).</p> Methods <p>A web-based data capture system stores patient demographics and aPL-related medical history. Inclusion criteria are positive aPL results, based on the revised Sapporo APS classification criteria, tested at least twice within one year prior to enrollment. For this cross-sectional analysis of the baseline data, demographic, clinical, and laboratory characteristics of registry patients were analyzed based on self-reported ethnorace (White, Latin American Mestizo [LAM], Asian, and Black).</p> Results <p>728 patients with no history of other SARD (78% with APS classification) were included in the analysis. The ethnoracial distribution was 516 (78%) White, 82 (12%) LAM, 49 (7%) Asian, and 13 (2%) Black. Based on ethnoracial comparisons: (a) there were less females among White patients; (b) livedo reticularis/racemosa was more frequent in LAM patients; and (c) triple aPL positivity was more frequent in Whites, while isolated lupus anticoagulant positivity was more common in LAM patients.</p> Conclusion <p>In our international registry of persistently aPL-positive patients with or without APS classification, Blacks were the least frequently (2%) reported ethnoracial group. No major ethnoracial differences were found in the aPL-related clinical manifestations. Our analysis highlights the need for further investigation into the genetic and social determinants impacting the clinical and serologic phenotypes of aPL-positive patients across diverse populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Do ethnoracial differences exist among antiphospholipid antibody-positive patients with no other systemic autoimmune diseases: results from the APS ACTION registry

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月16日

查看全文
  • Elena Gkrouzman,
  • Alicia Matijasevich,
  • Carolina Bonilla Richero,
  • Megan R. W. Barber,
  • Maria G. Tektonidou,
  • Vittorio Pengo,
  • Savino Sciascia,
  • Jose Pardos-Gea,
  • Mª Angeles Aguirre-Zamorano,
  • Nina Kello,
  • Diana Paredes-Ruiz,
  • H. Michael Belmont,
  • Paul R. Fortin,
  • Denis Wahl,
  • Ware Branch,
  • Maria Gerosa,
  • Flavio Signorelli,
  • Zhuoli Zhang,
  • Tatsuya Atsumi,
  • Maria Efthymiou,
  • Giulia Pazzola,
  • Cecillia Nalli,
  • Alí Duarte-García,
  • Esther Rodriguez Almaraz,
  • Michelle Petri,
  • Bahar Artim-Esen,
  • Guillermo Pons-Estel,
  • Hui Shi,
  • Jason S. Knight,
  • Rohan Willis,
  • Leslie Skeith,
  • Ann E. Clarke,
  • Massimo Radin,
  • Ariadna Anunciacion-Llunell,
  • Maria Laura Bertolaccini,
  • Hannah Cohen,
  • Ricard Cervera,
  • Danieli Castro Oliveira de Andrade,
  • Doruk Erkan

摘要

Objective

The APS ACTION Registry was created to study long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients. The objectives of this study were to examine the ethnoracial differences in clinical and laboratory characteristics of aPL-positive patients with no other systemic autoimmune rheumatic diseases (SARDs).

Methods

A web-based data capture system stores patient demographics and aPL-related medical history. Inclusion criteria are positive aPL results, based on the revised Sapporo APS classification criteria, tested at least twice within one year prior to enrollment. For this cross-sectional analysis of the baseline data, demographic, clinical, and laboratory characteristics of registry patients were analyzed based on self-reported ethnorace (White, Latin American Mestizo [LAM], Asian, and Black).

Results

728 patients with no history of other SARD (78% with APS classification) were included in the analysis. The ethnoracial distribution was 516 (78%) White, 82 (12%) LAM, 49 (7%) Asian, and 13 (2%) Black. Based on ethnoracial comparisons: (a) there were less females among White patients; (b) livedo reticularis/racemosa was more frequent in LAM patients; and (c) triple aPL positivity was more frequent in Whites, while isolated lupus anticoagulant positivity was more common in LAM patients.

Conclusion

In our international registry of persistently aPL-positive patients with or without APS classification, Blacks were the least frequently (2%) reported ethnoracial group. No major ethnoracial differences were found in the aPL-related clinical manifestations. Our analysis highlights the need for further investigation into the genetic and social determinants impacting the clinical and serologic phenotypes of aPL-positive patients across diverse populations.